The effect of magnesium in controlling asthma
Phase 2
- Conditions
- Asthma.Asthma, unspecified, Acute severe asthmaJ45.9,J46
- Registration Number
- IRCT20170827035935N2
- Lead Sponsor
- Vice chancellor for research of Mazandaran University of Medical Science
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Patients with asthma
Exclusion Criteria
Use of oral corticosteroids
Use Diuretics
Renal failure
Congestive heart failure
Use of magnesium supplement in the past quarter
History of using cigarettes
Pregnancy
The decision to have a pregnancy
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Severity of asthma. Timepoint: At the beginning of the study (before the intervention) and at weeks 4, 8 and 12 after the intervention. Method of measurement: PEFR measurements by peak flow meter.;FEV1/FVC. Timepoint: Before and immediately after the intervention. Method of measurement: Spirometry.;The number of asthma attacks. Timepoint: At the beginning of the study (before the intervention) and at weeks 4, 8 and 12 after the intervention. Method of measurement: Ask the patient.;ACT-Score. Timepoint: At the beginning of the study (before the intervention) and at weeks 4, 8 and 12 after the intervention. Method of measurement: ACT questionnaire.;FEV1. Timepoint: Before and immediately after the intervention. Method of measurement: Spirometry.;FVC. Timepoint: Before and immediately after the intervention. Method of measurement: Spirometry.
- Secondary Outcome Measures
Name Time Method -. Timepoint: -. Method of measurement: -.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie magnesium's bronchodilatory effects in asthma patients in IRCT20170827035935N2 phase II trial?
How does magnesium supplementation compare to beta-agonists/corticosteroids in acute severe asthma management?
Which biomarkers predict response to magnesium supplementation in J45.9/J46 asthma subtypes according to IRCT20170827035935N2?
What are the known adverse events of magnesium supplementation in asthma trials and their management strategies?
How does magnesium supplementation synergize with anticholinergic agents in managing refractory asthma symptoms in phase II studies?